San Diego, CA – On October 12, 2026, CanWell Pharma announced that it has been invited to attend the 17th World ADC San Diego 2026, taking place from October 13–14, 2026, in San Diego, USA, where the company will present its latest progress in multi-payload ADC research through two oral presentations and one poster presentation.
The presentations include the latest progress of CAN016, the first HER2-targeting dual-payload antibody-drug conjugate (ADC); the clinical development of CAN1012, a TLR7-selective agonist, together with the results of the i-ADC developed using it as a payload; and the preclinical research results of CAN018, a PD-L1-targeting dual-payload ADC. These innovative next-generation ADC candidates are expected to overcome tumor heterogeneity and drug resistance and to address highly unmet clinical needs in oncology.
Date: October 13 – 14, 2026
Address: San Diego, California, USA
Oral Presentation 1: Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients
Laying out the CAN016 preclinical profile, including monkey tox data supporting dual-payload ADC IND approval
Contextualizing the pre-IND filing approach as an emerging ADC modality, and the strategy for treating HER2 refractory patients
Highlighting the ongoing first-in-human development of CAN016 and its potential impact in HER2 refractory patients resistant to T-DXd
Date: Wednesday, October 14, 2026 Time: 11:00 AM
Oral Presentation 2: Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist for the Treatment of PD-1 Refractory Melanoma & Dedifferentiated Liposarcoma
Introducing CAN1012, a small molecule drug conjugate with a TLR7 agonist immunomodulatory payload
Laying out the rationale for liposarcoma indication selection and the CAN1012 early clinical data leading to Orphan Drug Designation
Understanding the importance of indication selection in underserved cancer indications to maximize ADC first-line potential and patient impact
Date: Wednesday, October 14, 2026 Time: 2:00 PM
Poster Presentation: CAN018, a PD-L1-targeted dual-payload ADC, demonstrates superior efficacy and a favorable safety profile in preclinical studies
Date: Wednesday, October 14, 2026
Poster Number: 93
CanWell Pharma looks forward to in-depth exchanges with peers from around the world on next-generation ADC development strategies at this conference, and to further expanding collaborations to jointly advance innovation and breakthroughs in ADC therapies.
About CanWell
CanWell Pharma is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class and best-in-class oncology therapies using its multi-payload ADC and small molecule drug conjugate (SMDC) platforms. CanWell is advancing a pipeline comprised of several candidates and two SMDC clinical candidates. The company’s leadership team has extensive experience in global drug development, having successfully advanced multiple programs through regulatory filings, clinical trials, and product approvals.
*To learn more about the meeting and the presentations, please visit the official World ADC website: World ADC San Diego 2026* https://worldadc-usa.com/
*Contact info: info@canwellpharma.com